Efficacy and safety of thromboprophylaxis in cancer patients: a systematic review and meta-analysis
Open Access
- 1 January 2020
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
Abstract
Thrombosis is a common complication in patients with cancer. Whether thromboprophylaxis could benefit patients with cancer is unclear. The aim of this systematic review was to determine the efficacy and safety of thromboprophylaxis in patients with cancer undergoing surgery or chemotherapy. We searched the Cochrane Library, EMBASE, MEDLINE, EBSCOhost, and Web of Science for studies published before May 2018 to investigate whether thromboprophylaxis measures were more effective than a placebo in patients with cancer. In total, 33 trials with 11,942 patients with cancer were identified. In patients with cancer undergoing surgery, the administration of thromboprophylaxis was associated with decreasing trends in venous thromboembolism (VTE) [relative risk (RR) 0.51, 95% confidence interval (CI) 0.32–0.81] and DVT (RR 0.53, 95% CI 0.33–0.87). In patients with cancer undergoing chemotherapy, the administration of thromboprophylaxis reduced the incidences of VTE, DVT, and pulmonary embolism compared with no thromboprophylaxis (RR 0.54, 95% CI 0.40–0.73; RR 0.47, 95% CI 0.31–0.73; RR 0.51, 95% CI 0.32–0.81, respectively). The pooled results regarding major bleeding showed no significant difference between prophylaxis and no prophylaxis in either the surgical or the chemotherapy groups (RR 2.35, 95% CI 0.74–7.52, p = 0.1482, I2 = 0%; RR 1.30, 95% CI 0.93–1.83, p = 0.1274, I2 = 0%, respectively). Thromboprophylaxis did not increase major bleeding events or the incidence of thrombocytopenia. All-cause mortality was not significantly different between those who received thromboprophylaxis and those who did not. This meta-analysis provides evidence that thromboprophylaxis can reduce the number of VTE and DVT events, with no apparent increase in the incidence of major bleeding in patients with cancer.Keywords
Funding Information
- Yuweihan Fund for Distinguished Young Scholars
- National Natural Science Foundation of China (81571871)
- National Natural Science Foundation of China (81770276)
- Harbin Medical University Cancer Hospital
- Harbin Medical University Cancer Hospital
This publication has 68 references indexed in Scilit:
- A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancerJournal of Thrombosis and Haemostasis, 2012
- Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung CancerClinical and Applied Thrombosis/hemostasis, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized studyJournal of Thrombosis and Haemostasis, 2010
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological diseaseThrombosis and Haemostasis, 2004
- Incidence of symptomatic venous thromboembolism after different elective or urgent surgical proceduresThrombosis and Haemostasis, 2003
- Safety of preoperative enoxaparin in head and neck cancer surgeryHead & Neck, 1995
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerThe Lancet, 1994